Implantable cardioverter-defibrillator shocks: Epidemiology, outcomes, and therapeutic approaches

JAMA Internal Medicine

Volumn 173, Issue 10, 2013, Pages 859-865

  Borne, Ryan T ^a,d   Varosy, Paul D ^b,c,d   Masoudi, Frederick A ^c,d  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b Veterans Affairs Eastern Colorado Health Care System   (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SOTALOL;

CARDIOGENIC SHOCK; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CATHETER ABLATION; CONVULSIVE THERAPY; DRUG DOSE INCREASE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART FAILURE; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MEDICAL LITERATURE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SINUS TACHYCARDIA; SUDDEN CARDIAC DEATH; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; EXERCISE; HEALTH STATUS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84878515688     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.428     Document Type: Review

References (63)

1. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303(6):322-324. (Pubitemid 10040022)
2. Moss AJ, Zareba W, Hall WJ, et al; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883. (Pubitemid 34984635)
3. Kadish A, Dyer A, Daubert JP, et al Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-2158. (Pubitemid 38637995)
4. Bardy GH, Lee KL, Mark DB, et al Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237. (Pubitemid 40110811)
5. Hammill SC, Kremers MS, Stevenson LW, et al. Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm. 2010;7(9):1340-1345.
6. Ahmad M, Bloomstein L, Roelke M, Bernstein AD, Parsonnet V. Patients' attitudes toward implanted defibrillator shocks. Pacing Clin Electrophysiol. 2000;23(6):934-938. (Pubitemid 30413598)
7. Mishkin JD, Saxonhouse SJ, Woo GW, et al. Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock. J Am Coll Cardiol. 2009;54(22):1993-2000.
8. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009-1017.
9. Klein RC, Raitt MH, Wilkoff BL, et al AVID Investigators. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol. 2003;14(9):940-948. (Pubitemid 37115157)
10. Daubert JP, Zareba W, Cannom DS, et al; MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51(14):1357-1365. (Pubitemid 351443082)
11. Ellenbogen KA, Levine JH, Berger RD, et al Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation. 2006;113(6):776-782.
12. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576-1583.
13. Germano JJ, Reynolds M, Essebag V, Josephson ME. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol. 2006;97(8):1255-1261.
14. Saxon LA, Hayes DL, Gilliam FR, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation. 2010;122(23):2359-2367.
15. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation. 2008;117(15):1918-1926. (Pubitemid 351543467)
16. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol. 2004;15(9):1002-1009. (Pubitemid 39281528)
17. Gehi AK, Mehta D, Gomes JA. Evaluation and management of patients after implantable cardioverter-defibrillator shock. JAMA. 2006;296(23):2839-2847. (Pubitemid 44969184)
18. Hauser RG, Hayes DL. Increasing hazard of Sprint Fidelis implantable cardioverter-defibrillator lead failure. Heart Rhythm. 2009;6(5):605-610.
19. Valk S, Luijten R, Jordaens L. Insulation damage in a shock wire: an unexpected fluoroscopic image. Pacing Clin Electrophysiol. 2010;33(6):770-772.
20. Richards MW, Warren CE, Anderson MH. Late failure of a single-coil transvenous implantable cardioverter-defibrillator lead associated with conductor separation. Europace. 2010;12(8):1191-1192.
21. Sung RK, Massie BM, Varosy PD, et al. Long-term electrical survival analysis of Riata and Riata ST silicone leads: National Veterans Affairs experience. Heart Rhythm. 2012;9(12):1954-1961.
22. Himmrich E, Przibille O, Zellerhoff C, et al. Proarrhythmic effect of pacemaker stimulation in patients with implanted cardioverter-defibrillators. Circulation. 2003;108(2):192-197. (Pubitemid 36871302)
23. Josephson ME. Recurrent Ventricular Tachycardia. Clinical Cardiac Electrophysiology: Techniques and Interpretations. Philadelphia, PA: Lippincott, Williams & Wilkins; 2002.
24. Steinberg JS, Fischer A, Wang P, et al; MADIT II Investigators. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J Cardiovasc Electrophysiol. 2005;16(4):359-365.
25. Wilkoff BL, Cook JR, Epstein AE, et al Dual Chamber and VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288(24):3115-3123. (Pubitemid 36014128)
26. Vollmann D, Lüthje L, Vonhof S, Unterberg C. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm. 2005;2(3):307-309. (Pubitemid 40309831)
27. Mark DB, Anstrom KJ, Sun JL, et al Sudden Cardiac Death in Heart Failure Trial Investigators. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med. 2008;359(10):999-1008.
28. Schron EB, Exner DV, Yao Q, et al. Quality of life in the Antiarrhythmics versus Implantable Defibrillators Trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105(5):589-594. (Pubitemid 34123433)
29. Sears SF Jr, Todaro JF, Lewis TS, Sotile W, Conti JB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol. 1999;22(7):481-489. (Pubitemid 29302759)
30. Hegel MT, Griegel LE, Black C, Goulden L, Ozahowski T. Anxiety and depression in patients receiving implanted cardioverter-defibrillators: a longitudinal investigation. Int J Psychiatry Med. 1997;27(1):57-69. (Pubitemid 27306661)
31. Dougherty CM. Psychological reactions and family adjustment in shock versus no shock groups after implantation of internal cardioverter defibrillator. Heart Lung. 1995;24(4):281-291.
32. Luderitz B, Jung W, Deister A, Manz M. Quality of Life in Multiprogrammable Implantable Cardioverter-Defibrillator Recipients: Interventional Electrophysiology: A Textbook. In: Saskena S, Luderitz B, eds. Armonk, NY: Futura Publishing Co Inc; 1996:305-313.
33. Godemann F, Butter C, Lampe F, et al. Panic disorders and agoraphobia: side effects of treatment with an implantable cardioverter/defibrillator. Clin Cardiol. 2004;27(6):321-326. (Pubitemid 38703084)
34. Moss AJ, Greenberg H, Case RB, et al Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110(25):3760-3765. (Pubitemid 40023973)
35. Sweeney MO, Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7(3):353-360.
36. Nasir NJ Jr, Pacifico A, Doyle TK, Earle NR, Hardage ML, Henry PD; Cadence Investigators. Spontaneous ventricular tachycardia treated by antitachycardia pacing. Am J Cardiol. 1997;79(6):820-822. (Pubitemid 27152350)
37. Estes NA III, Haugh CJ, Wang PJ, Manolis AS. Antitachycardia pacing and low-energy cardioversion for ventricular tachycardia termination: a clinical perspective. Am Heart J. 1994;127(4 Pt 2):1038-1046.
38. Wathen MS, DeGroot PJ, Sweeney MO, et al; Pain-FREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (Pain-FREE Rx II) trial results. Circulation. 2004;110(17):2591-2596. (Pubitemid 39453007)
39. Wilkoff BL, Williamson BD, Stern RS, et al PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52(7):541-550.
40. Moss AJ, Schuger C, Beck CA, et al MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367(24):2275-2283.
41. Brugada J, Mont L, Figueiredo M, Valentino M, Matas M, Navarro-López F. Enhanced detection criteria in implantable defibrillators. J Cardiovasc Electrophysiol. 1998;9(3):261-268. (Pubitemid 28180463)
42. Klein GJ, Gillberg JM, Tang A, et al Worldwide Wave Investigators. Improving SVT discrimination in single-chamber ICDs: a new electrogram morphology-based algorithm. J Cardiovasc Electrophysiol. 2006;17(12):1310-1319. (Pubitemid 44808550)
43. Kühlkamp V, Dörnberger V, Mewis C, Suchalla R, Bosch RF, Seipel L. Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing. J Cardiovasc Electrophysiol. 1999;10(7):905-915. (Pubitemid 29297709)
44. Deisenhofer I, Kolb C, Ndrepepa G, et al. Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? a randomized, prospective study. J Cardiovasc Electrophysiol. 2001;12(2):134-142. (Pubitemid 32171500)
45. Theuns DA, Klootwijk AP, Goedhart DM, Jordaens LJ. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. J AmColl Cardiol. 2004;44(12):2362-2367. (Pubitemid 39647611)
46. Friedman PA, McClelland RL, Bamlet WR, et al. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the Detect Supraventricular Tachycardia Study. Circulation. 2006;113(25):2871-2879. (Pubitemid 44297227)
47. Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Am Coll Cardiol. 2011;58(10):1007-1013.
48. Cheng A, Wang Y, Curtis JP, Varosy PD. Acute lead dislodgements and in-hospital mortality in patients enrolled in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. J Am Coll Cardiol. 2010;56(20):1651-1656.
49. Hjalmarson A, Goldstein S, Fagerberg B, et al MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283(10):1295-1302. (Pubitemid 30129796)
50. Packer M, Bristow MR, Cohn JN, et al U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334(21):1349-1355. (Pubitemid 26152713)
51. Packer M, Coats AJ, Fowler MB, et al Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-1658. (Pubitemid 32479962)
52. Flather MD, Yusuf S, Køber L, et al ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355(9215):1575-1581. (Pubitemid 30240501)
53. Bapoje SR, Bahia A, Hokanson JE, et al. The effects of mineral corticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a metaanalysis of randomized controlled trials. Cir Heart Fail. http://circheartfailure.ahajournals.org/content/early/ 2013/02/12/CIRCHEARTFAILURE.112.000003.abstract.html. Accessed February 12, 2013.
54. Hauptman PJ, Swindle JP, Masoudi FA, Burroughs TE. Underutilization of β-blockers in patients undergoing implantable cardioverter-defibrillator and cardiac resynchronization procedures. Circ Cardiovasc Qual Outcomes. 2010;3(2):204-211.
55. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation. 2005;112(1):39-47. (Pubitemid 40962567)
56. Connolly SJ, Dorian P, Roberts RS, et al Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165-171. (Pubitemid 43076435)
57. Lehmann MH, Hardy S, Archibald D, Quart B, Mac-Neil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94(10):2535- 2541.
58. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791-798.
59. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B; Practice Guidelines Subcommitee, North American Society of Pacing, Electrophysiology. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000;160(12):1741-1748.
60. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357(26):2657- 2665.
61. Epstein AE, DiMarco JP, Ellenbogen KA, et al American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51(21):e1-e62. http://content.onlinejacc. org/article.aspx?articleid=1138927. Accessed December 10, 2012. (Pubitemid 351689050)
62. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60(4):1297-1313. http://content.onlinejacc.org/article.aspx? articleid=1357576. Accessed December 10, 2012.
63. Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA. 2011;305(1):43-49.